Medicine RSS Search Engine

Cilostazol Cilostazol RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

This page shows you the latest news and research items in this category.

Improvement in in vitro fertilization outcome following in vivo synchronization of oocyte maturation in mice
This study was therefore designed to define the effect of in vivo synchronization of oocyte maturation on IVF rates. Mice were superovulated and orally treated with 7.5 mg cilostazol (CLZ), a phosphodiesterase 3A (PDE3A) inhibitor, to induce ovulation of immature oocytes at different stages depending on frequency and time of administration of CLZ. Mice treated with CLZ ovulated germinal vesicle (GV) or metaphase I (MI) oocytes that underwent maturation in vitro or in vivo (i.e. in the oviduct) followed by IVF. Superovulated control mice ovulated mature oocytes that underwent IVF directly upon collection. Ovu...
Source: Experimental Biology and Medicine - April 15, 2015 Category: Research Authors: Taiyeb, A. M., Muhsen-Alanssari, S. A., Dees, W., Ridha-Albarzanchi, M. T., Kraemer, D. C. Tags: Pharmacology/Toxicology Source Type: research

Serum uric acid is positively associated with cerebral white matter hyperintensities in patients with acute lacunar infarction: Subgroup analysis of the Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse) study (P1.046)
CONCLUSIONS: This study showed that WMH volume was positively associated with serum UA in patients with acute lacunar infarction. Our findings indicate that impaired cerebrovascular hemodynamics may be associated with cerebral WMH. Study Supported by: NoneDisclosure: Dr. Han has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Park has nothing to disclose. Dr. Park has nothing to disclose. (Source: Neurology)
Source: Neurology - April 8, 2015 Category: Neurology Authors: Han, S. W., Lee, J. Y., Lee, K.-Y., Park, J. H., Park, J. H. Tags: Cerebrovascular Disease and Interventional Neurology: The Spectrum of Small Vessel Cerebrovascular Disease Source Type: research

CILOSTAZOL Tablet [Golden State Medical Supply, Inc.]
Updated Date: Mar 30, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - March 30, 2015 Category: Drugs & Pharmacology Source Type: news

Preconditioning by Cilostazol Protects against Cold Hepatic Ischemia-Reperfusion Injury.
Conclusions Inhibition of PDE3 reduces endothelial cell activation and hepatocellular injury in cold ischemia/reperfusion of the liver. PMID: 25811412 [PubMed - as supplied by publisher] (Source: Annals of Transplantation)
Source: Annals of Transplantation - March 27, 2015 Category: Transplant Surgery Authors: von Heesen M, Müller S, Keppler U, Strowitzki MJ, Scheuer C, Schilling MK, Menger MD, Moussavian MR Tags: Ann Transplant Source Type: research

Retraction Note: Systematic study of cilostazol on secondary stroke prevention: a meta-analysis
(Source: European Journal of Medical Research)
Source: European Journal of Medical Research - March 26, 2015 Category: Research Source Type: research

Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
CONCLUSIONS: Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. This could be a novel strategy for cardioembolic stroke prevention potentially by affecting cardiac remodelling, in contrast to secondary anticoagulant therapy. PMID: 25798683 [PubMed - as supplied by publisher] (Source: Neurological Research)
Source: Neurological Research - March 24, 2015 Category: Neurology Tags: Neurol Res Source Type: research

Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis
Antiplatelet therapy is recommended for patients who have experienced ischemic stroke. We performed a meta-analysis to compare the efficacy and safety of cilostazol with other antiplatelet therapies in patients with ischemic stroke. (Source: Journal of Stroke and Cerebrovascular Diseases)
Source: Journal of Stroke and Cerebrovascular Diseases - March 24, 2015 Category: Neurology Authors: Liang Tan, Barnhart Margaret, John H. Zhang, Rong Hu, Yi Yin, Liu Cao, Hua Feng, Yanqi Zhang Source Type: research

Efficacy of Antiplatelet Therapy in Secondary Prevention Following Lacunar Stroke: Pooled Analysis of Randomized Trials [Clinical Sciences]
Conclusions— Our results suggest that any of the single antiplatelet agents compared with placebo in the included trials is adequate for secondary stroke prevention after lacunar stroke. Dual antiplatelet therapy should not be used for long-term stroke prevention in this stroke subtype. (Source: Stroke)
Source: Stroke - March 23, 2015 Category: Neurology Authors: Kwok, C. S., Shoamanesh, A., Copley, H. C., Myint, P. K., Loke, Y. K., Benavente, O. R. Tags: Antiplatelets Clinical Sciences Source Type: research

Optimal- vs. standard-antiplatelet therapy on platelet function and long-term clinical outcomes in patients with high on-treatment platelet reactivity: 2-year outcomes of the multicentre, randomized Optimal-antiPlatelet Therapy (OPT) trial
Optimal strategy for the management of high on-treatment platelet reactivity (HPR), an independent predictor of ischaemic events, is not yet clear. The aim of this study was to explore the safety and efficacy of personalized antiplatelet therapy based on platelet function testing in patients with HPR. A total of 840 patients with HPR who underwent coronary stenting for acute coronary syndrome (ACS) were randomly assigned in a 1:2 ratio to receive standard dual-antiplatelet therapy (n = 280) or platelet function-guided optimal-antiplatelet therapy (n = 560). In the optimal group, patients initially received clopidogrel 150 ...
Source: European Journal of Heart Failure Supplements - March 23, 2015 Category: Cardiology Authors: Li, Y., Han, Y., Guan, S., Sun, Y., Guo, L., Yang, B., Zang, H., Jing, Q., Wang, X., Ma, Y., Liu, X., Li, J., Zheng, L. Tags: Articles Source Type: research

CILOSTAZOL Tablet [Apotex Corp.]
Updated Date: Mar 13, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - March 13, 2015 Category: Drugs & Pharmacology Source Type: news

Acute myocardial infarction after cilostazol use in a patient with systemic lupus erythematosus
Anaphylaxis is a life-threatening allergic reaction that is rapid in onset and which can cause sudden death. Kounis syndrome (KS) is the concurrence of acute coronary syndromes combined with allergic or hypersensitivity and anaphylactic reactions [1]. Cilostazol is a medication for the treatment of intermittent claudication [2], but which can enhance allergic complications [3]. Herein, we describe a case of cilostazol-induced KS in a 66-year-old female with systemic lupus erythematosus (SLE). (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - March 11, 2015 Category: Cardiology Authors: Jincheng Guo, Wenming Chen, Guozhong Wang, Fuli Zhu Tags: Letter to the editor Source Type: research

Clinical Efficacy and Safety of Cilostazol: A Critical Review of the Literature
Abstract Cilostazol is a unique antiplatelet agent that has been commercially available for over two decades. As a phosphodiesterase III inhibitor, it reversibly inhibits platelet aggregation yet also possesses vasodilatory and antiproliferative properties. It has been widely studied in a variety of disease states, including peripheral arterial disease, cerebrovascular disease, and coronary artery disease with percutaneous coronary intervention. Overall, cilostazol appears to be a promising agent in the management of these disease states with a bleeding profile comparable to placebo; even when combined with other ...
Source: Drugs - March 10, 2015 Category: Drugs & Pharmacology Source Type: research

Intervention or Exercise? The Answer Is Yes! ∗
Intermittent claudication is the most common symptomatic form of peripheral artery disease (PAD). The magnitude of the disability from claudication is severe, such that patients report a marked decrease in their quality of life (1). Despite vigorous investigative efforts, only 4 treatments reliably reduce disability and increase walking distance: cilostazol; exercise training; percutaneous angioplasty and stenting; and surgical bypass. Cilostazol, an oral phosphodiesterase-3 inhibitor, modestly increases walking distance and rarely returns patients to full functional status (2). Therapies currently recommended most to reli...
Source: Journal of the American College of Cardiology - March 9, 2015 Category: Cardiology Source Type: research

CILOSTAZOL Tablet [Roxane Laboratories, Inc]
Updated Date: Mar 5, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - March 5, 2015 Category: Drugs & Pharmacology Source Type: news

Cilostazol induces vasodilation through the activation of Ca(2+)-activated K(+) channels in aortic smooth muscle.
Abstract We investigated the vasorelaxant effect of cilostazol and related signaling pathways in phenylephrine (Phe)-induced pre-contracted aortic rings. Cilostazol induced vasorelaxation in a concentration-dependent manner when aortic rings were pre-contracted with Phe. Application of the voltage-dependent K(+) (Kv) channel inhibitor 4-AP, the ATP-sensitive K(+) (KATP) channel inhibitor glibenclamide, and the inwardly rectifying K(+) (Kir) channel inhibitor Ba(2+) did not alter the vasorelaxant effect of cilostazol; however, pre- and post-treatment with the big-conductance Ca(2+)-activated K(+) (BKCa) channel inhi...
Source: Vascular Pharmacology - March 5, 2015 Category: Drugs & Pharmacology Authors: Li H, Hong DH, Son YK, Na SH, Jung WK, Bae YM, Seo EY, Kim SJ, Choi IW, Park WS Tags: Vascul Pharmacol Source Type: research

Hemichorea in a diabetes mellitus patient following acute ischemic stroke with changes in regional cerebral blood flow
Publication date: Available online 4 March 2015 Source:Journal of the Chinese Medical Association Author(s): Yutaka Suzuki , Minoru Oishi , Akira Kanno , Katsuhiko Ogawa , Mariko Fujisawa , Satoshi Kamei It is not unusual to observe hemichorea in patients with diabetes mellitus, with origins attributable to recent ischemia. Our patient was a 66-year-old female with diabetes mellitus who suddenly developed right hemichorea, mild muscle weakness of the right upper extremity, ideational apraxia, and acalculia. Her blood glucose was 600 mg/dL, and HbA1c was 13.3%. After the patient underwent head magnetic resonance imaging ...
Source: Journal of the Chinese Medical Association - March 4, 2015 Category: Journals (General) Source Type: research

Cilostazol research in Asia: can it be applied to European and American patients?
Cilostazol is an antiplatelet drug often used in Asian countries like Korea, Japan, and China. However, it is rarely used in the west. Cilostazol inhibits phosphodiesterase, increases cyclic AMP concentrations, and consequently inhibits platelet aggregation. Interestingly, it also has vasodilatory activity, inhibits vascular smooth muscle proliferation, and protects the endothelium. Studies in Asia have shown that cilostazol is effective in the secondary prevention of stroke. Moreover, it is significantly less likely to cause bleeding complications than aspirin. Additional trials have shown that cilostazol is effective in ...
Source: International Journal of Stroke - March 4, 2015 Category: Neurology Authors: Jong S. Kim, Sun U. Kwon, Shinichiro Uchiyama Tags: Leading Opinion (Invited) Source Type: research

Cilostazol improves hepatic blood perfusion, microcirculation and liver regeneration after major hepatectomy in rats
Conclusion: Cilostazol increases hepatic blood perfusion, microcirculation and liver regeneration after major hepatectomy. Thus, cilostazol may represent a novel strategy to reduce the rate of liver failure after both extended hepatectomy and small‐for‐size liver transplantation. This article is protected by copyright. All rights reserved. (Source: Liver Transplantation)
Source: Liver Transplantation - March 1, 2015 Category: Transplant Surgery Authors: Maximilian von Heesen, Stefan Dold, Simon Müller, Claudia Scheuer, Otto Kollmar, Martin K. Schilling, Michael D. Menger, Mohammed R. Moussavian Tags: Original Article Source Type: research

[Prospective, Systematic Observational Study on the Daily Use of Cilostazol (Pletal®) in Clinical Vascular Surgical Practice - Significant Improvement of Walking Distance and Quality of Life for Patients with PAOD, Stage II b.]
Conclusion: Medication with cilostazol led to a significant increase of the maximum walking distance (p < 0.0001) compared to the initial distance, which was further increased through one year (however, the effect became weaker) accompanied by a dominating improvement of the quality of life. The effects can be observed longer than 3-6 months. PMID: 25723863 [PubMed - as supplied by publisher] (Source: Zentralblatt fur Chirurgie)
Source: Zentralblatt fur Chirurgie - February 27, 2015 Category: Surgery Authors: Weber M, Weber T, Meyer F, Halloul Z Tags: Zentralbl Chir Source Type: research

Pletal (Cilostazol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 13, 2015 Category: Drugs & Pharmacology Source Type: news

Wetting Kinetics: an Alternative Approach Towards Understanding the Enhanced Dissolution Rate for Amorphous Solid Dispersion of a Poorly Soluble Drug.
Abstract Developing amorphous solid dispersions of water-insoluble molecules using polymeric materials is a well-defined approach to improve the dissolution rate and bioavailability. While the selected polymer plays a vital role in stabilizing the amorphous solid dispersion physically, it is equally important to improve the dissolution profile by inhibiting crystallization from the supersaturated solution generated by dissolution of the amorphous material. Furthermore, understanding the mechanism of dissolution rate enhancement is of vital importance. In this work, wetting kinetics was taken up as an alternative ap...
Source: AAPS PharmSciTech - February 12, 2015 Category: Drugs & Pharmacology Authors: Verma S, Rudraraju VS Tags: AAPS PharmSciTech Source Type: research

Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products
Abstract Recent studies have demonstrated that the plasma soluble receptor for advanced glycation end-products (sRAGE) play a major role in developing macrovascular complications of type 2 diabetes, including peripheral arterial occlusion disease (PAOD). Cilostazol is an antiplatelet, antithrombotic agent, which has been used for the treatment of PAOD. We hypothesized that cilostazol attenuates the severity of PAOD in patients with type 2 diabetes through the augmentation of plasma sRAGE. Ninety type 2 diabetic patients with PAOD defined as intermittent claudication with ankle-brachial index (ABI) ≦0.9 were recr...
Source: Endocrine - February 10, 2015 Category: Endocrinology Source Type: research

PLETAL (Cilostazol) Tablet [Otsuka America Pharmaceutical, Inc.]
Updated Date: Feb 9, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 9, 2015 Category: Drugs & Pharmacology Source Type: news

Antiplatelet Therapy for Peripheral Arterial Disease and Critical Limb Ischemia: Guidelines Abound, But Where Are the Data?
This article summarizes the major guidelines for antiplatelet therapy, reviews the major studies of antiplatelet therapy in peripheral arterial disease (including data for aspirin, clopidogrel, dipyridamole, cilostazol, and prostanoids), and offers perspective on the potential benefits of ticagrelor, vorapaxar, and rivaroxaban. The review concludes with a discussion of the relative lack of efficacy that antiplatelet therapy has shown in regard to peripheral vascular outcomes. (Source: Journal of Cardiovascular Pharmacology and Therapeutics)
Source: Journal of Cardiovascular Pharmacology and Therapeutics - February 9, 2015 Category: Cardiology Authors: Azarbal, A., Clavijo, L., Gaglia, M. A. Tags: Review Articles Source Type: research

Cilostazol attenuates cholestatic liver injury and its complications in common bile duct ligated rats.
Abstract Cilostazol is a phosphodiesterase III inhibitor increases adenosine 3', 5'-cyclic monophosphate (cyclic AMP) level which inhibits hepatic stellate cell activation. Its pharmacological effects include vasodilation, inhibition of vascular smooth muscle cell growth, inhibition of platelet activation and aggregation. The aim of the current study was to determine the effects of early administration of low dose cilostazol on cholestatic liver injury induced by common bile duct ligation (CBDL) in rat. Male Wistar rats (180-200g) were divided into three groups: Group A; simple laparotomy group (sham). Group B; CBD...
Source: European Journal of Pharmacology - February 6, 2015 Category: Drugs & Pharmacology Authors: Abdel Kawy HS Tags: Eur J Pharmacol Source Type: research

Phosphodiesterase 3 (PDE3) inhibition with Cilostazol does not block in vivo oocyte maturation in rhesus macaques
Studies in mice suggest that cilostazol, an FDA-approved phosphodiesterase 3 (PDE3) inhibitor, might have a contraceptive effect within the approved dose range. We sought to evaluate the potential contraceptive effects of cilostazol in a non-human primate model. (Source: Contraception)
Source: Contraception - January 30, 2015 Category: OBGYN Authors: Carol B. Hanna, Shan Yao, Cathy M. Ramsey, Jon D. Hennebold, Mary B. Zelinski, Jeffrey T. Jensen Tags: Original Research Article Source Type: research

Cilostazol but not sildenafil prevents memory impairment after chronic cerebral hypoperfusion in middle-aged rats.
Abstract We previously reported that the phosphodiesterase-5 (PDE5) inhibitor sildenafil prevented neurodegeneration but not learning deficits in middle-aged rats that were subjected to the permanent, three-stage, four-vessel occlusion/internal carotid artery (4-VO/ICA) model of chronic cerebral hypoperfusion (CCH). In the present study, we examined whether the PDE3 inhibitor cilostazol alleviates the loss of long-term memory (i.e., retrograde amnesia) caused by CCH. The effect of sildenafil was then compared to cilostazol. Naive rats (12-15 months old) were trained in a non-food-rewarded eight-arm radial maze and ...
Source: Behavioural Brain Research - January 23, 2015 Category: Neurology Authors: Godinho J, Oliveira JN, Ferreira ED, Zaghi GG, Bacarin CC, Oliveira RM, Milani H Tags: Behav Brain Res Source Type: research

Neuroprotective effects of cilostazol are mediated by multiple mechanisms in a mouse model of permanent focal ischemia.
Abstract The phosphodiesterase (PDE) 3 inhibitor cilostazol, used as an anti-platelet drug, reportedly can also ameliorate ischemic brain injury. Here, we investigated the effects of cilostazol in a permanent focal ischemia mice model. Male Balb/c mice were subjected to permanent middle cerebral artery occlusion. Mice were then treated with either cilostazol (10 or 20mg/kg) or vehicle administered at 30min and 24h post-ischemia, and infarct volumes were assessed at 48h post-ischemia. Mice treated with 20mg/kg of cilostazol or vehicle were sacrificed at 6h or 24h post-ischemia and immunohistochemistry was used for b...
Source: Brain Research - January 21, 2015 Category: Neurology Authors: Shichinohe H, Tan C, Abumiya T, Nakayama N, Kazumata K, Hokari M, Houkin K, Kuroda S Tags: Brain Res Source Type: research

Final Results of Cilostazol-Aspirin Therapy against Recurrent Stroke with Intracranial Artery Stenosis (CATHARSIS)
Conclusion: Progression of IAS during the 2-year observation period appears to be less frequent than previously reported in stroke patients on antiplatelet agents after the acute phase, which could be due to the adequate control of risk factors, and because patients with stroke within 2 weeks after the onset were excluded. The results of the CATHARSIS trial suggest a potential utility of pharmacotherapies with cilostazol plus aspirin as well as of strict control of risk factors for the management of symptomatic IAS. Larger studies with higher statistical power are required to obtain conclusive results.Cerebrovasc Dis Extra...
Source: Cerebrovascular Diseases Extra - January 15, 2015 Category: Neurology Source Type: research

Cilostazol improves high glucose-induced impaired angiogenesis in human endothelial progenitor cells and vascular endothelial cells as well as enhances vasculoangiogenesis in hyperglycemic mice mediated by the adenosine monophosphate-activated protein kinase pathway
This study investigated the effects of cilostazol in preventing high glucose (HG)-induced impaired angiogenesis and examined the potential mechanisms involving activation of AMP-activated protein kinase (AMPK). (Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - January 13, 2015 Category: Surgery Authors: Shih-Ya Tseng, Ting-Hsing Chao, Yi-Heng Li, Ping-Yen Liu, Cheng-Han Lee, Chung-Lung Cho, Hua-Lin Wu, Jyh-Hong Chen Source Type: research

Cilostazol and freedom from amputation after lower extremity revascularization
Cilostazol, an antiplatelet agent with vasodilating properties, has not been well evaluated in conjunction lower extremity revascularization (LER). We evaluated the association between cilostazol and limb salvage after endovascular or open surgery for LER. (Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - January 13, 2015 Category: Surgery Authors: J. David Neel, Robin L. Kruse, Viktor Y. Dombrovskiy, Todd R. Vogel Tags: Clinical Paper Source Type: research

Enhancement of solubility and dissolution of cilostazol by solid dispersion technique.
Abstract Cilostazol is practically insoluble in water and thus results in poor bioavailability. Only a few approaches have been reported for improving the bioavailability of cilostazol. Solid dispersion technique via solvent evaporation method was applied to improve the solubility and dissolution of cilostazol. Various polymers, mixture of polymer and surfactant, and mixture of polymers were screened as a carrier for the solid dispersion. Solubility of cilostazol was improved significantly when Eudragit(®) L100 was used as a carrier. However, addition of surfactant to Eudragit(®) L100 decreased the solubility sli...
Source: Archives of Pharmacal Research - January 8, 2015 Category: Drugs & Pharmacology Authors: Park J, Choi H Tags: Arch Pharm Res Source Type: research

Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials
Abstract The aim of this study was to obtain best estimates of the efficacy and safety of cilostazol-based triple antiplatelet therapy (TAPT: aspirin, clopidogrel and cilostazol) compared with dual antiplatelet therapy (DAPT: aspirin and clopidogrel) in patients undergoing coronary stent implantation. We searched the literature to identify all randomized clinical trials examining efficacy and safety of TAPT versus DAPT in patients undergoing coronary stent implantation. Major efficacy outcomes were death, non-fatal myocardial infarction (MI), ischemic stroke and stent thrombosis (ST) and the safety outcome was bl...
Source: Journal of Thrombosis and Thrombolysis - January 1, 2015 Category: Hematology Source Type: research

The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population- an updated meta-analysis
Conclusion: Cilostazolprovided a protective effect in the secondary prevention of the chronic phase ofischemic stroke. (Source: BMC Neurology)
Source: BMC Neurology - December 20, 2014 Category: Neurology Authors: LiGen ShiJiaLi PuLiang XuJay MalaguitJianmin ZhangSheng Chen Source Type: research

Profile of atherosclerotic risk factors and management in patients of peripheral arterial disease at a tertiary care teaching hospital of North India
The objectives of the present study were to characterize the atherosclerotic risk factor profile and pattern of drug prescription for patients of peripheral arterial disease at a tertiary care teaching hospital and to compare this management with standard guidelines. Data were collected from prescriptions of patients attending cardiothoracic and vascular surgery outpatient department with diagnosis of atherosclerotic peripheral arterial disease from July 2012 to Jun 2013. One hundred twenty prescriptions were analysed. The mean age (&#177;SD) of patients was 53&#177;7.18 years and 23.3% were females. H...
Source: Indian Journal of Pharmaceutical Sciences - December 17, 2014 Category: Drugs & Pharmacology Authors: U AimanMA HaseenMH BegRA KhanFA SiddiquiI Alam Source Type: research

Retrospective review of superficial femoral artery stenting in diabetic patients: thiazolidinedione use may decrease reinterventions
Conclusions: This pilot, translation study demonstrates that diabetic patients taking thiazolidinediones at the time of primary SFA stenting have decreased reintervention rates at 2 years. These results may be explained by higher adiponectin levels or other anti-inflammatory effects in patients taking thiazolidinedione. National and regional quality improvement registries should consider collecting information regarding specific diabetic regimens and use of PPAR agonists such as cilostazol and fibrates. (Source: BMC Cardiovascular Disorders)
Source: BMC Cardiovascular Disorders - December 11, 2014 Category: Cardiology Authors: Karen WalkerDaniel WalshPhilip GoodneySamantha ConnellDavid StoneRichard PowellEva Rzucidlo Source Type: research

Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open‐label, parallel‐group trial
DiscussionThe CSPS.com is expected to provide evidence indicating whether secondary IS prevention in high‐risk patients can be improved by using DAPT involving cilostazol. (Source: International Journal of Stroke)
Source: International Journal of Stroke - December 8, 2014 Category: Neurology Authors: Kazunori Toyoda, Shinichiro Uchiyama, Haruhiko Hoshino, Kazumi Kimura, Hideki Origasa, Hiroaki Naritomi, Kazuo Minematsu, Takenori Yamaguchi, Tags: Protocols Source Type: research

The effect of cilostazol and aspirin pre-treatment against subsequent transient focal cerebral ischemia in rat.
We examined whether 7 days of oral administration of cilostazol protects against subsequent cerebral ischemia, and whether or not the effect of combination therapy with aspirin is more protective. METHODS: We used Sprague-Dawley (SD) rats and assigned them to four groups: vehicle, aspirin, cilostazol, and aspirin plus cilostazol combination therapy. After oral administration of anti-platelets for 7 days, we performed transient middle cerebral artery occlusion (MCAO) for 90 minutes, and examined infarct volume, neurological symptoms, and regional cerebral blood flow (rCBF). Immunostaining of Bax, Bcl-2, TUNEL, 4-HNE, 8-...
Source: Neurological Research - December 2, 2014 Category: Neurology Tags: Neurol Res Source Type: research

The response of carotid intima-media thickness to medical treatment is correlated with that of intracranial atherosclerosis.
CONCLUSIONS: The ICAS response may be associated with the CIMT response to medical treatment. PMID: 24285964 [PubMed] (Source: Journal of Clinical Neurology)
Source: Journal of Clinical Neurology - December 2, 2014 Category: Neurology Tags: J Clin Neurol Source Type: research

Contemporary Medical Management of Peripheral Arterial Disease
Peripheral arterial disease (PAD) is primarily caused by progressive systemic atherosclerosis manifesting in the lower extremities. This review addresses the epidemiology, clinical presentation and evaluation, and medical management of PAD, with a focus on intermittent claudication. Key advances in the recognition of cardiovascular risk in asymptomatic individuals with mildly abnormal ankle-brachial index, newer reflections on exercise therapy, and a review of established and investigational agents for the treatment of symptomatic PAD, such as cilostazol, statins, and angiotensin-converting enzyme inhibitors, are highlight...
Source: Cardiology Clinics - November 29, 2014 Category: Cardiology Authors: Kush Agrawal, Robert T. Eberhardt Source Type: research

Topical Cilostazol Inhibits Neointimal Hyperplasia in a Rat Interposition Vein Graft Model
Conclusions: A single intraoperative dose of cilostazol applied locally significantly reduced intima size and smooth muscle content in rat interposition vein grafts examined 4 weeks postoperatively. A topical dose of cilostazol at surgery may therefore be helpful in controlling neointimal hyperplasia and reducing the need for systemic medications to prolong vein graft patency. (Source: Plastic and Reconstructive Surgery)
Source: Plastic and Reconstructive Surgery - November 24, 2014 Category: Cosmetic Surgery Tags: Experimental: Original Articles Source Type: research

Drug-drug interactions associated with antiplatelet therapy.
Authors: Dunn SP, Macaulay TE Abstract Antiplatelet therapy is of paramount importance in the treatment and prevention of adverse cardiovascular events and stroke. Drug-drug interactions (DDIs) among antiplatelet therapies have been growing in both prevalence and clinical importance. Most DDIs with antiplatelet therapies are pharmacodynamic in nature. DDIs with thienopyridines and proton pump inhibitors have resulted in advisories from regulatory agencies although the full significance of this interaction is unknown. Other DDIs with thienopyridines may potentially exist with statins, calcium channel blockers, and w...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - November 23, 2014 Category: Cardiology Tags: Cardiovasc Hematol Agents Med Chem Source Type: research

Cilostazol Attenuates Spinal Cord Ischemia-Reperfusion Injury in Rabbits
The aim of this study was to evaluate the pretreatment effect of cilostazol on spinal cord ischemia-reperfusion injury. (Source: Journal of Cardiothoracic and Vascular Anesthesia)
Source: Journal of Cardiothoracic and Vascular Anesthesia - November 19, 2014 Category: Anesthesiology Authors: Yunus Nazli, Necmettin Colak, Mehmet Namuslu, Husamettin Erdamar, Hacer Haltas, Mehmet Fatih Alpay, Omer Nuri Aksoy, Ismail Olgun Akkaya, Omer Cakir Tags: Orıgınal Artıcles Source Type: research

Population Pharmacokinetic Analysis of Diurnal and Seasonal Variations of Plasma Concentrations of Cilostazol in Healthy Volunteers
Conclusions: This study demonstrated the intraday and interseasonal time-varying nature of cilostazol pharmacokinetics using a population modeling approach and developed a strategy for optimizing dosing times. It is suggested that these methods can be similarly applied to analyses and controls of other drugs that exhibit characteristics of time-varying pharmacokinetics. (Source: Therapeutic Drug Monitoring)
Source: Therapeutic Drug Monitoring - November 15, 2014 Category: Drugs & Pharmacology Tags: Original Article Source Type: research

The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double‐blind, placebo‐controlled multicenter trial
ConclusionThe SPAD trial is the first study to evaluate the safety and efficacy of dual antiplatelet agents, aspirin plus cilostazol, in comparison with aspirin alone in patients with both ischemic stroke or TIA and PAD. Results from this trial will provide important information on the merit of adding cilostazol to aspirin for slowing down progression of atherosclerosis in patients with ischemic stroke and PAD. (Source: International Journal of Stroke)
Source: International Journal of Stroke - November 14, 2014 Category: Neurology Authors: Jiann‐Shing Jeng, Yu Sun, Jiunn‐Tay Lee, Ruey‐Tay Lin, Chih‐Hung Chen, Helen L. Po, Huey‐Juan Lin, Chung‐Hsiang Liu, Ming‐Hui Sun, Mu‐Chien Sun, Chang‐Ming Chern, Li‐Ming Lien, Hou‐Chang Chiu, Han‐Hwa Hu, Hung‐Yi Chiou, Sien‐Ts Tags: Protocols Source Type: research

Practical Method for Preparing Nanosuspension Formulations for Toxicology Studies in the Discovery Stage: Formulation Optimization and in Vitro/in Vivo Evaluation of Nanosized Poorly Water-Soluble Compounds.
In conclusion, applying a wet media milling method with the combination of HPMC of a small molecular weight and Tween 80 as a dispersing agent, nanosuspensions can be practically prepared and conveniently utilized for enhancing the oral absorption of poorly water-soluble compounds in toxicology studies in the discovery stage. PMID: 25366311 [PubMed - in process] (Source: Chemical and Pharmaceutical Bulletin)
Source: Chemical and Pharmaceutical Bulletin - November 10, 2014 Category: Drugs & Pharmacology Authors: Komasaka T, Fujimura H, Tagawa T, Sugiyama A, Kitano Y Tags: Chem Pharm Bull (Tokyo) Source Type: research

Cilostazol Decreases Cerebral Arterial Pulsatility in Patients with Mild White Matter Hyperintensities: Subgroup Analysis from the Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse) Study
Conclusions: This study showed that cilostazol decreased cerebral arterial pulsatility in patients with WMH. Our findings indicate the unique effect of cilostazol in small vessel disease (SVD), especially in patients with mild WMH changes. Further clinical trials focusing on WMH volume and clinical outcomes are required to assess the unique efficacy of cilostazol in SVD.Cerebrovasc Dis 2014;38:197-203 (Source: Cerebrovascular Diseases)
Source: Cerebrovascular Diseases - November 7, 2014 Category: Neurology Source Type: research

Cilostazol for intermittent claudication.
CONCLUSIONS: Cilostazol has been shown to be of benefit in improving walking distance in people with intermittent claudication secondary to PAD. Although there is an increase in adverse side effects, they are generally mild and treatable. There is currently insufficient data on whether taking cilostazol results in a reduction of all-cause mortality and cardiovascular events or an improvement in quality of life. Future research into the effect of cilostazol on intermittent claudication should carefully consider comparability, sample size and homogeneity when designing a study. PMID: 25358850 [PubMed - in process] (Sourc...
Source: Cochrane Database of Systematic Reviews - November 5, 2014 Category: Journals (General) Authors: Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G Tags: Cochrane Database Syst Rev Source Type: research

Cilostazol attenuates ischemia–reperfusion-induced blood–brain barrier dysfunction enhanced by advanced glycation endproducts via transforming growth factor-β1 signaling
Publication date: May 2014 Source:Molecular and Cellular Neuroscience, Volume 60 Author(s): Tomonori Takeshita , Shinsuke Nakagawa , Rie Tatsumi , Gohei So , Kentaro Hayashi , Kunihiko Tanaka , Maria A. Deli , Izumi Nagata , Masami Niwa We investigated the effects of cilostazol, a selective inhibitor of phosphodiesterase 3, on blood–brain barrier (BBB) integrity against ischemia–reperfusion injury enhanced by advanced glycation endproducts (AGEs). We used in vitro BBB models with primarily cultured BBB-related cells from rats (brain capillary endothelial cells, astrocytes and pericytes), and subjected cells to either...
Source: Molecular and Cellular Neuroscience - November 3, 2014 Category: Neuroscience Source Type: research

In vitro and in vivo evaluation of self-nanoemulsifying drug delivery systems of cilostazol for oral and parenteral administration
Publication date: 10 December 2014 Source:International Journal of Pharmaceutics, Volume 476, Issues 1–2 Author(s): Dina B. Mahmoud , Marwa H. Shukr , Ehab R. Bendas The current investigation was aimed to improve the solubility of poorly soluble drug, cilostazol (CLZ). Self-nanoemulsifying drug delivery system (SNEDDS) composed of oil, surfactant and co-surfactant for both oral and parenteral administration of CLZ was formulated. The components for SNEDDS were identified by solubility studies, and pseudo-ternary phase diagrams were plotted to identify the efficient self-emulsification regions. The optimum formula, comp...
Source: International Journal of Pharmaceutics - November 3, 2014 Category: Drugs & Pharmacology Source Type: research